Tags

Type your tag names separated by a space and hit enter

[Dexamethason implant in the treatment of macular edema in retinal vein occlusion and intraocular inflammatory disease].
Klin Monbl Augenheilkd. 2013 Apr; 230(4):396-400.KM

Abstract

BACKGROUND

The efficacy of a single dose of Ozurdex® was evaluated over a 6-month period in eyes with macular edema due to retinal vein occlusion and intraocular inflammatory disease.

HISTORY AND SIGNS

20 eyes of 20 consecutive patients with macular edema received a single injection of Ozurdex® (intravitreal dexamethasone implant 0.7 mg). Patients with branch retinal vein occlusion (n = 11), central retinal vein occlusion (n = 6), non-infectious posterior uveitis (n = 1) and Irvine-Gass Syndrome (n = 2) were included. In 10 patients Ozurdex® was used as the first treatment, 10 patients had undergone previous treatments for macular edema. The mean duration from the symptoms to the initiation of the treatment was 14.2 (1-60) months. The follow-up measurements were performed 1, 3 and 6 months after treatment. The main interest of the study was the visual and structural development over the duration of 6 months after a single dose of Ozurdex® with outcome measures including changes in best-corrected visual acuity and central retinal thickness.

THERAPY AND OUTCOME

At baseline, the mean best-corrected visual acuity of all patients was 50 (± 16) ETDRS letters and the mean central retinal thickness was 632 (± 168.3) microns. Mean follow-up time was 3.4 (± 1.5) months and 7 patients dropped out during the follow-up period (4 patients after 3 months, additional 3 patients after 6 months). One month after treatment, 14 out of 20 patients (70%) showed a complete regression of macular edema, and in 6 cases (30%) it was partially recurrent. The mean best-corrected visual acuity improved to 56 (± 20.8) ETDRS. Central retinal thickness showed a mean decrease to 278 (± 84.9) microns. 6 months after treatment, recurrence was observed in 9 cases out of the remaining 13 patients (69.2%). In 3 cases, macular edema persisted (23.1%) and in one case (7.7%) the macula remained dry. The mean best-corrected visual acuity was 55 (± 13.9) ETDRS letters. The mean central retinal thickness decreased to 603 (± 174.6) microns.

CONCLUSIONS

Ozurdex® showed a good effect in the treatment of macular edema one month after its application, namely a temporary decrease in central retinal thickness and a corresponding increase in best-corrected visual acuity. 6 months after treatment, the recurrence rate was high, and only one person with a branch retinal vein occlusion remained relapse-free over the entire follow-up. Based on our data, the patients should be checked at the latest after 3 months and then monthly in order to detect relapse in time and to initiate another treatment if needed.

Authors+Show Affiliations

Department of Ophthalmology, Cantonal Hospital St Gallen, St. Gallen, Switzerland.No affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
English Abstract
Journal Article

Language

ger

PubMed ID

23629790

Citation

Brunner, M, et al. "[Dexamethason Implant in the Treatment of Macular Edema in Retinal Vein Occlusion and Intraocular Inflammatory Disease]." Klinische Monatsblatter Fur Augenheilkunde, vol. 230, no. 4, 2013, pp. 396-400.
Brunner M, Haueter I, Valmaggia C. [Dexamethason implant in the treatment of macular edema in retinal vein occlusion and intraocular inflammatory disease]. Klin Monbl Augenheilkd. 2013;230(4):396-400.
Brunner, M., Haueter, I., & Valmaggia, C. (2013). [Dexamethason implant in the treatment of macular edema in retinal vein occlusion and intraocular inflammatory disease]. Klinische Monatsblatter Fur Augenheilkunde, 230(4), 396-400. https://doi.org/10.1055/s-0032-1328365
Brunner M, Haueter I, Valmaggia C. [Dexamethason Implant in the Treatment of Macular Edema in Retinal Vein Occlusion and Intraocular Inflammatory Disease]. Klin Monbl Augenheilkd. 2013;230(4):396-400. PubMed PMID: 23629790.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Dexamethason implant in the treatment of macular edema in retinal vein occlusion and intraocular inflammatory disease]. AU - Brunner,M, AU - Haueter,I, AU - Valmaggia,C, Y1 - 2013/04/29/ PY - 2013/5/1/entrez PY - 2013/5/1/pubmed PY - 2013/12/16/medline SP - 396 EP - 400 JF - Klinische Monatsblatter fur Augenheilkunde JO - Klin Monbl Augenheilkd VL - 230 IS - 4 N2 - BACKGROUND: The efficacy of a single dose of Ozurdex® was evaluated over a 6-month period in eyes with macular edema due to retinal vein occlusion and intraocular inflammatory disease. HISTORY AND SIGNS: 20 eyes of 20 consecutive patients with macular edema received a single injection of Ozurdex® (intravitreal dexamethasone implant 0.7 mg). Patients with branch retinal vein occlusion (n = 11), central retinal vein occlusion (n = 6), non-infectious posterior uveitis (n = 1) and Irvine-Gass Syndrome (n = 2) were included. In 10 patients Ozurdex® was used as the first treatment, 10 patients had undergone previous treatments for macular edema. The mean duration from the symptoms to the initiation of the treatment was 14.2 (1-60) months. The follow-up measurements were performed 1, 3 and 6 months after treatment. The main interest of the study was the visual and structural development over the duration of 6 months after a single dose of Ozurdex® with outcome measures including changes in best-corrected visual acuity and central retinal thickness. THERAPY AND OUTCOME: At baseline, the mean best-corrected visual acuity of all patients was 50 (± 16) ETDRS letters and the mean central retinal thickness was 632 (± 168.3) microns. Mean follow-up time was 3.4 (± 1.5) months and 7 patients dropped out during the follow-up period (4 patients after 3 months, additional 3 patients after 6 months). One month after treatment, 14 out of 20 patients (70%) showed a complete regression of macular edema, and in 6 cases (30%) it was partially recurrent. The mean best-corrected visual acuity improved to 56 (± 20.8) ETDRS. Central retinal thickness showed a mean decrease to 278 (± 84.9) microns. 6 months after treatment, recurrence was observed in 9 cases out of the remaining 13 patients (69.2%). In 3 cases, macular edema persisted (23.1%) and in one case (7.7%) the macula remained dry. The mean best-corrected visual acuity was 55 (± 13.9) ETDRS letters. The mean central retinal thickness decreased to 603 (± 174.6) microns. CONCLUSIONS: Ozurdex® showed a good effect in the treatment of macular edema one month after its application, namely a temporary decrease in central retinal thickness and a corresponding increase in best-corrected visual acuity. 6 months after treatment, the recurrence rate was high, and only one person with a branch retinal vein occlusion remained relapse-free over the entire follow-up. Based on our data, the patients should be checked at the latest after 3 months and then monthly in order to detect relapse in time and to initiate another treatment if needed. SN - 1439-3999 UR - https://www.unboundmedicine.com/medline/citation/23629790/[Dexamethason_implant_in_the_treatment_of_macular_edema_in_retinal_vein_occlusion_and_intraocular_inflammatory_disease]_ L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/s-0032-1328365 DB - PRIME DP - Unbound Medicine ER -